Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder.

Calarge C, Farmer C, DiSilvestro R, Arnold LE.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):495-502. doi: 10.1089/cap.2010.0053.

2.

Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine.

Arnold LE, Disilvestro RA, Bozzolo D, Bozzolo H, Crowl L, Fernandez S, Ramadan Y, Thompson S, Mo X, Abdel-Rasoul M, Joseph E.

J Child Adolesc Psychopharmacol. 2011 Feb;21(1):1-19. doi: 10.1089/cap.2010.0073.

3.

The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.

Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM.

J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14. doi: 10.1089/cap.2014.0176. Epub 2015 Feb 18.

4.

Iron Deficiency Parameters in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Percinel I, Yazici KU, Ustundag B.

Child Psychiatry Hum Dev. 2016 Apr;47(2):259-69. doi: 10.1007/s10578-015-0562-y.

PMID:
26092605
5.

Iron deficiency in children with attention-deficit/hyperactivity disorder.

Konofal E, Lecendreux M, Arnulf I, Mouren MC.

Arch Pediatr Adolesc Med. 2004 Dec;158(12):1113-5.

PMID:
15583094
6.

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.

8.

Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.

Weisler RH, Babcock T, Adeyi B, Brams M.

Postgrad Med. 2014 Sep;126(5):31-41. doi: 10.3810/pgm.2014.09.2798.

PMID:
25295648
9.

Effects of iron supplementation on attention deficit hyperactivity disorder in children.

Konofal E, Lecendreux M, Deron J, Marchand M, Cortese S, Zaïm M, Mouren MC, Arnulf I.

Pediatr Neurol. 2008 Jan;38(1):20-6.

PMID:
18054688
10.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
11.

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3.

PMID:
21421179
14.

Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.

Wang LJ, Chen CK, Huang YS.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):246-53. doi: 10.1089/cap.2014.0015. Epub 2015 Jan 9.

PMID:
25574708
15.

Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.

Waxmonsky JG, Waschbusch DA, Glatt SJ, Faraone SV.

J Clin Psychiatry. 2011 Oct;72(10):1366-75. doi: 10.4088/JCP.10m05979pur.

PMID:
21367347
17.

Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.

Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12.

PMID:
22780921
18.

Iron and ADHD: time to move beyond serum ferritin levels.

Donfrancesco R, Parisi P, Vanacore N, Martines F, Sargentini V, Cortese S.

J Atten Disord. 2013 May;17(4):347-57. doi: 10.1177/1087054711430712. Epub 2012 Jan 30.

PMID:
22290693
19.

Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.

Calarge CA, Murry DJ, Ziegler EE, Arnold LE.

J Child Adolesc Psychopharmacol. 2016 Jun;26(5):471-7. doi: 10.1089/cap.2015.0194. Epub 2016 Feb 19.

20.

Supplemental Content

Support Center